Liu X, et al. - Researchers assessed data to delineate the significance of myeloblastosis (MYB) as a prognostic marker for individuals with adenoid cystic carcinoma (ACC) vs MYB gene fusion, MYB protein expression, and tumor sites. They recorded 57.2% and 62.3% of the combined positive rates of MYB gene fusion and protein expression, respectively. They overall did not observe significant prognostic differences between MYB-positive and MYB-negative ACCs. No significant differences were noticed for any survival outcome like overall survival, disease-free survival, and local control rate when further divided into MYB gene fusion and MYB protein expression subgroups. They did not demonstrate any prognostic value of MYB in head and neck ACCs.